Advanced Prostate Cancer COE

ESMO 2020 Expert Clinical Conversation on Prostate Cancer - Oliver Sartor

Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss several developing and practice-changing prostate cancer studies from some of the key data presented at the European Society of Medical Oncology (ESMO) 2020 Virtual Congress. Dr. Sartor and Dr. Morgans review topline results from three oral presentations. They discuss the data from IPATential150 - a phase III study of ipatasertib plus abir...

A Prostate Cancer Community: Driving Access to Resources for Patients and Providers of Care - Felix Feng and Charles Ryan

Details
Alicia Morgans, MD, MPH is joined by Felix Feng, MD, and Charles Ryan, MD in a conversation reflecting on their personal commitments to furthering the understanding and treatment of prostate cancer. The Month of September recognized as Prostate Cancer Awareness Month highlights the commitment each of them delivers every day of every month to their patients and to all prostate cancer patients aroun...

Lower Odds of Cardiac Events for Gonadotropin Releasing Hormone Antagonists versus Agonists - Eugene Cone

Details
Eugene Cone, MD, a urologic oncology fellow at Harvard Medical School, joins Tom Keane, MBBCh, FRCSI, FACS, to discuss the increased risk of cardiac events associated with androgen deprivation therapy, the standard of care for prostate cancer treatment, and the differences in cardiac risk between gonadotropin-releasing antagonists versus agonists. Dr. Cone’s research compared traditional gonadotro...

PROSPER Trial Journal Club: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer - Zachary Klaassen and Christopher J.D. Wallis

Details
In this Journal Club, Zachary Klaassen and Christopher Wallis review the recently published New England Journal of Medicine article Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, the double-blind, phase 3 PROSPER trial. Men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months)...

Journal Club: Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen host this journal club on "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer," published by the HERO trial investigators in the New England Journal of Medicine simultaneously with the first presentation of the trial results at the ASCO 2020 annual meeting. Sharing background information on androgen deprivation therapy (ADT), as well...

HERO Phase III Trial: Results Comparing Relugolix, an Oral GnRH Receptor Antagonist Vs. Leuprolide Acetate for Advanced Prostate Cancer - Neal Shore

Details
Relugolix is the first oral GnRH receptor antagonist, which was previously shown to rapidly suppress testosterone levels. Neal Shore joins Alicia Morgans to discuss the results of the HERO phase 3 trial comparing the safety and efficacy of relugolix with leuprolide acetate in advanced prostate cancer patients. Relugolix is an oral, once a day medication, and the trial had a primary endpoint of non...

The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study - Mary-Ellen Taplin

Details
Mary-Ellen Taplin, Professor of Medicine Harvard Medical School and a GU Medical Oncologist at the Dana-Farber Cancer Institute, joins Alicia Morgans to discuss the ProGen study. A randomized controlled trial that aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer. This...

The Impact of Treatment Delays on Prostate Cancer During the COVID-19 Pandemic - Zach Klaassen & Chris Wallis

Details
Recorded Date: April 24, 2020 Christopher Wallis and Zachary Klaassen join Alicia Morgans to discuss the management guidance released by European Urology on how to best optimize the care of prostate cancer patients during the COVID-19 pandemic. In this Journal Club, Dr. Klaassen and Dr. Wallis assess the impact of delaying treatment in patients with prostate cancer and discuss the potential conseq...

The Ethics of Delivering Precision Medicine — Hala Borno

Details
Hala Borno joins Alicia Morgans and discusses a recent viewpoint article in JAMA Oncology titled “The Ethics of Delivering Precision Medicine—Pretest Counseling and Somatic Genomic Testing.” In the new era of precision medicine in cancer treatment, many clinicians use patient tumor genomic (somatic) data as part of routine clinical practice. Dr. Borno shares insights into Pretest Counseling in an...

Low Carbohydrate Diets in Men with Recurrent Prostate Cancer: The CAPS2 Study - Stephen Freedland

Details
Stephen Freedland joins Alicia Morgans to discuss the Carbohydrate and Prostate Study 2 (CAPS2), a randomized controlled trial of a 6-month low carbohydrate intervention on disease progression in men with recurrent prostate cancer. This study is part of a series of studies looking at the role of low carbohydrate diets in prostate cancer. The study involved taking men with rising PSA after failed s...